Taysha Gene Therapies, Inc.
Financials
Valuation Metrics
Taysha Gene Therapies, Inc.'s Market Cap is $1.64B. At end of 2025 it was $1.76B. Ranked #2151 of 3,121 in US market (top 69%), #844 of 1,463 on NASDAQ (top 58%), #154 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.64B | US#2,151/3,121 Sec#154/266 |
| Revenue | $5M | US#2,850/3,121 Sec#179/266 |
| Net Income | $-150M | US—/3,121 Sec—/266 |
| Total Assets | $470M | US#2,796/3,121 Sec#172/266 |
| Net Assets | $387M | US#2,394/3,121 Sec#137/266 |
| Employees | 99 | US#2,634/3,121 Sec#181/266 |
| Value | ||
| P/B | 4.22x | US#2,100/3,121 Sec#129/266 |
| P/S | 298.21x | US#2,971/3,121 Sec#190/266 |
| FCF Yield | -8.29% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -38.64% | US#2,621/3,121 Sec#134/266 |
| ROA | -31.81% | US#2,898/3,121 Sec#162/266 |
| Op. Margin | -2792.32% | US#2,846/3,121 Sec#172/266 |
| Revenue Growth | -32.27% | US#2,722/3,121 Sec#159/266 |
| Financial Health | ||
| Debt Ratio | 21.48% | US#246/3,121 Sec#84/266 |
| Total Debt | $56M | US#2,595/3,121 Sec#151/266 |
| FCF | $-136M | US#2,700/3,121 Sec#169/266 |
| Cash | $455M | US#1,132/3,121 Sec#61/266 |
| Current Ratio | 17.76x | US#138/3,121 Sec#35/266 |
| Performance | ||
| 1Y Return | 67.89% | US#313/3,121 Sec#80/266 |
| 1M Return | -21.93% | US#2,885/3,121 Sec#232/266 |
| From 52W High | -31.23% | US#2,029/3,121 Sec#160/266 |
| 1Y MDD | -31.13% | US#1,502/3,121 Sec#96/266 |
| Trading | ||
| Volume | 7,655,307 shares | US#575/3,121 Sec#52/266 |
| Trading Value | $39M | US#2,044/3,121 Sec#160/266 |
| Per Share | ||
| EPS | $-0.46 | US—/3,121 Sec—/266 |
| BPS | $1.19 | US#2,672/3,121 Sec#199/266 |
Company Info
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.